Ethical and Clinical Considerations in the Use of Hydroxyurea in Pregnant Women with Sickle Cell Disease

References

• Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14(1):263–292. doi: 10.1146/annurev-pathmechdis-012418-012838.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World J. 2008; 8:1295–1324. doi: 10.1100/tsw.2008.157.
   Web of Science ®Google Scholar
• O Ntim E, Daveena M,TS, Louise W, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125(21):3316–3326.
   PubMed Web of Science ®Google Scholar
• Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. Obstet Anesth Dig. 2017;37(1):9–10. doi: 10.1097/01.aoa.0000511999.06517.f5.
   Google Scholar
• Desai G, Anand A, Shah P, et al. Sickle cell disease and pregnancy outcomes: a study of the community-based hospital in a tribal block of Gujarat, India. J Health Popul Nutr. 2017;36(1):3–3. doi: 10.1186/s41043-017-0079-z.
   PubMedGoogle Scholar
• Lesage N, Deneux Tharaux C, Saucedo M, et al. Maternal mortality among women with sickle-cell disease in France, 1996-2009. Eur J Obstet Gynecol Reprod Biol. 2015;194:183–188. doi: 10.1016/j.ejogrb.2015.09.016.
   PubMed Web of Science ®Google Scholar
• Asnani MR, McCaw-Binns AM, Reid ME. Excess risk of maternal death from sickle cell disease in Jamaica: 1998-2007. PLoS One. 2011;6(10):e26281. doi: 10.1371/journal.pone.0026281.
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute. The management of sickle cell diseasees [Internet]. 2004. p. 1–188. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf.
   Google Scholar
• Sickle Cell Disease in Pregnancy. Management of (Green-top Guideline No. 61) [Internet]. RCOG. Available from: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/sickle-cell-disease-in-pregnancy-management-of-green-top-guideline-no-61/.
   Google Scholar
• Research C for DE and FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia. FDA [Internet]. 2019. Feb 9; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-hydroxyurea-treatment-pediatric-patients-sickle-cell-anemia
   Google Scholar
• Central Drugs Standard Control Organisation Directorate General of Health Services Ministry of Health &Family Welfare, Government of India.
   Google Scholar
• Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline - Oteng‐Ntim - 2021. British Journal of Haematology - Wiley Online Library [Internet]. Available from: doi: 10.1111/bjh.17671.
   Google Scholar
• Montironi R, Cupaiolo R, Kadji C, et al. Management of sickle cell disease during pregnancy: experience in a third-level hospital and future recommendations. J Matern Fetal Neonatal Med. 2022;35(12):2345–2354. doi: 10.1080/14767058.2020.1786054.
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008; 148(12):939–955. doi: 10.7326/0003-4819-148-12-200806170-00221.
   PubMed Web of Science ®Google Scholar
• Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022;9(9):CD002202.
   PubMedGoogle Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048. doi: 10.1001/jama.2014.10517.
   Google Scholar
• Khera KS. A teratogenicity study on hydroxyurea and diphenylhydantoin in cats. Teratology. 1979;20(3):447–452. doi: 10.1002/tera.1420200314.
   PubMedGoogle Scholar
• Chahoud I, Paumgartten FJR. Dose-response relationships of rat fetal skeleton variations: relevance for risk assessment. Environ Res. 2009;109(7):922–929. doi: 10.1016/j.envres.2009.07.013.
   PubMed Web of Science ®Google Scholar
• Amortegui AJ, Klionsky B, Surti U, et al. Experimental intrauterine fetal growth retardation in the rat: effect of a single dose of hydroxyurea or cycloheximide on the fetus at term. Prog Clin Biol Res. 1983;140:13–26.
   PubMedGoogle Scholar
• Kroner BL, Hankins JS, Pugh N, et al. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 2022;97(5):603–612. doi: 10.1002/ajh.26495.
   PubMed Web of Science ®Google Scholar
• Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046–1051. doi: 10.1016/s0027-9684(15)31072-5.
   PubMed Web of Science ®Google Scholar
• Gellen-Dautremer J, Le Jeune S, Receveur MC, et al. Hydroxyurea exposure throughout pregnancy in patients with sickle-cell disease: 4 case reports from European Non-Interventional, Multicentric, Prospective Escort-HU study. Blood. 2019;134(Supplement_1):1027–1027. doi: 10.1182/blood-2019-126529.
   Google Scholar
• Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol. 1993; 85(1):203–204. doi: 10.1111/j.1365-2141.1993.tb08672.x.
   PubMed Web of Science ®Google Scholar
• Silva FAC, Ferreira ALCG, Pimentel LM, et al. The use of hydroxyurea during pregnancy in sickle cell anemia women: a case series and literature review. J Hematol Res. 2021; 8:6–10. doi: 10.12974/2312-5411.2021.08.2.
   Google Scholar
• Hou JW. Fetal warfarin syndrome. Chang Gung Med J. 2004; 27(9):691–695.
   PubMedGoogle Scholar
• Middeldorp S, Vandvik PO, Bates SM, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2012;141(2 Suppl):e691S–e736S. doi: 10.1378/chest.11-2300.
   PubMedGoogle Scholar
• Soma-Pillay P, Nene Z, Mathivha TM, et al. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstet Med. 2011; 4(1):24–27. doi: 10.1258/om.2010.100067.
   PubMedGoogle Scholar
• Nelson-Piercy C. Management of antithrombotic therapy for a prosthetic heart valve during pregnancy. UptoDate [Internet]. 2019. Available from: https://www.uptodate.com/contents/management-of-antithrombotic-therapy-for-a-prosthetic-heart-valve-during-pregnancy#H1497381286.
   Google Scholar
• Frequently Asked Questions (FAQs) on New Drugs and Clinical Trials. Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India. [Internet]. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/faqnd.pdf.
   Google Scholar